The company exhibits extreme revenue volatility, with quarterly figures fluctuating between $0.8M and $19.6M, while operating margins remain deeply negative at -88.0% as of 2026Q1.
| Sales/Revenue | 36.82M | 18.62M | 10.9M | 9.56M | 9.22M | 9.33M | 6.79M | 2.32M | 379K |
| Revenue Growth % | 312.41% | 70.85% | 13.99% | 3.64% | -1.09% | 37.41% | 192.67% | 511.87% | - |
| Cost of Goods Sold | 138.28M | 0 | 0 | 2.1M | 1.39M | 101.18M | 37.6M | 0 | 8.44M |
| COGS % of Revenue | - | - | - | 21.98% | 15.04% | 1084.95% | 554.03% | - | 2225.86% |
| Gross Profit | -101.46M | 18.62M | 10.9M | 7.46M | 7.84M | -91.86M | -30.82M | 2.32M | -8.06M |
| Gross Margin % | -275.59% | 100% | 100% | 78.02% | 84.96% | -984.95% | -454.03% | 100% | -2125.86% |
| Gross Profit Growth % | - | 70.85% | 46.09% | -4.82% | 108.53% | -198.09% | -1428.81% | 128.78% | - |
| Operating Expenses | 323.8M | 95.43M | 389.83M | 243.06M | 186.75M | 26.2M | 13.46M | 19.65M | 10.88M |
| OpEx % of Revenue | - | 512.58% | 3577.43% | 2542.44% | 2024.61% | 280.88% | 198.35% | 847.39% | 2869.92% |
| Selling, General & Admin | 133.7M | 41.68M | 86.24M | 54.19M | 37.73M | 26.2M | 13.46M | 5.11M | 2.44M |
| SG&A % of Revenue | - | 223.85% | 791.41% | 566.84% | 409.07% | 280.88% | 198.35% | 220.44% | 644.06% |
| Research & Development | 328.23M | 53.76M | 303.59M | 190.97M | 150.4M | 101.18M | 37.6M | 14.54M | 8.44M |
| R&D % of Revenue | - | 288.73% | 2786.02% | 1997.57% | 1630.57% | 1084.95% | 554.03% | 626.95% | 2225.86% |
| Other Operating Expenses | -1000K | 0 | 0 | -2.1M | -1.39M | -101.18M | -37.6M | 0 | 0 |
| Operating Income | -425.26M | -76.81M | -378.94M | -235.6M | -178.91M | -118.05M | -44.28M | -17.33M | -10.5M |
| Operating Margin % | -1155.1% | -412.58% | -3477.43% | -2464.41% | -1939.65% | -1265.83% | -652.38% | -747.39% | -2769.92% |
| Operating Income Growth % | - | 79.73% | -60.84% | -31.68% | -51.56% | -166.62% | -155.46% | -65.1% | - |
| EBITDA | -423.12M | -76.49M | -376.16M | -233.5M | -177.53M | -117.41M | -43.9M | -16.98M | -10.12M |
| EBITDA Margin % | -1149.28% | -410.84% | -3451.96% | -2442.44% | -1924.61% | -1258.97% | -646.88% | -732.38% | -2668.87% |
| EBITDA Growth % | 1.68% | 79.67% | -61.1% | -31.53% | -51.2% | -167.43% | -158.5% | -67.91% | - |
| D&A (Non-Cash Add-back) | 2.14M | 323K | 2.78M | 2.1M | 1.39M | 639K | 373K | 348K | 383K |
| EBIT | -410.9M | -76.81M | -378.94M | -235.6M | -178.91M | -118.05M | -44.15M | -17.35M | -10.5M |
| Net Interest Income | 29.22M | 0 | 56.88M | 23.97M | 4.97M | 104K | -3K | -7.39M | -718K |
| Interest Income | 29.22M | 0 | 56.88M | 23.97M | 4.97M | 104K | 206K | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 209K | 7.39M | 718K |
| Other Income/Expense | 28.84M | -12K | 56.63M | 23.38M | 4.92M | 42K | -78K | -7.4M | -718K |
| Pretax Income | -396.43M | -76.83M | -322.3M | -212.22M | -174M | -118.01M | -44.35M | -24.73M | -11.22M |
| Pretax Margin % | -1076.77% | -412.64% | -2957.71% | -2219.87% | -1886.33% | -1265.38% | -653.53% | -1066.58% | -2959.37% |
| Income Tax | 34K | -142K | 0 | 0 | 0 | 0 | 0 | 0 | 718K |
| Effective Tax Rate % | -0.01% | 0.18% | 0% | 0% | 0% | 0% | 0% | 0% | -6.4% |
| Net Income | -396.46M | -76.68M | -322.3M | -212.22M | -174M | -118.01M | -44.35M | -24.73M | -11.93M |
| Net Margin % | -1076.87% | -411.88% | -2957.71% | -2219.87% | -1886.33% | -1265.38% | -653.53% | -1066.58% | -3148.81% |
| Net Income Growth % | -7.38% | 76.21% | -51.87% | -21.97% | -47.44% | -166.06% | -79.33% | -107.26% | - |
| Net Income (Continuing) | -396.46M | -76.68M | -322.3M | -212.22M | -174M | -118.01M | -44.35M | -24.73M | -11.22M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -23.18 | -4.48 | -2.89 | -2.91 | -3.34 | -2.85 | -2.05 | -0.86 | -0.58 |
| EPS Growth % | -71.1% | -55.02% | 0.69% | 12.87% | -17.19% | -39.02% | -138.37% | -48.28% | - |
| EPS (Basic) | - | -4.48 | -2.89 | -2.91 | -3.34 | -2.85 | -2.05 | -0.86 | -0.58 |
| Diluted Shares Outstanding | 17.11M | 17.11M | 111.58M | 73.01M | 52.16M | 41.43M | 21.66M | 37.51M | 20.68M |
| Basic Shares Outstanding | 17.11M | 17.11M | 111.58M | 73.01M | 52.16M | 41.43M | 21.66M | 37.51M | 20.68M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Clinical trial execution failure
As reported in financial statements, Atrium Therapeutics exhibits highly erratic revenue patterns, with quarterly figures fluctuating between $0.8M and $19.6M, reflecting the non-recurring nature of collaboration milestones rather than consistent commercial demand, which complicates any attempt to model a predictable top-line growth trajectory for the firm.
The revenue profile is entirely dependent on the timing of R&D milestones, which creates significant quarter-over-quarter variance that should not be mistaken for organic commercial growth. Investors should monitor the underlying clinical progress rather than these headline figures, as the current revenue stream lacks the durability required for long-term valuation stability.
Based on recent SEC filings, the company's R&D expenditure reached a peak of $154.9M in 2025Q3, illustrating a massive capital commitment to clinical infrastructure that dwarfs current revenue inflows and underscores the firm's status as a pre-commercial entity heavily reliant on external financing to sustain operations.
The cost structure is dominated by high-intensity clinical trial expenses, which are necessary to validate the AOC platform but create a persistent drag on the income statement. This expense discipline appears secondary to the urgency of clinical advancement, suggesting that cost management will remain secondary to trial success for the foreseeable future.
According to the provided income statement data, the company maintains a deeply negative operating margin, reaching -412.58% at its worst, which indicates that the firm has yet to achieve any meaningful operating leverage as R&D and G&A costs continue to scale independently of revenue.
The lack of operating leverage is expected for a biotech at this stage, but the magnitude of the losses suggests that the company is far from reaching a self-sustaining financial model. Any future improvement in operating margins will likely require a successful transition to commercial-stage manufacturing or a significant reduction in clinical trial overhead.
As evidenced by the quarterly data, the company consistently issues significant stock-based compensation, with figures reaching $19.0M in 2025Q3, which effectively masks the true cash burn required to support the firm's ongoing clinical development programs and dilutes existing shareholders in the process.
The reliance on equity-based incentives is a standard practice in the sector, yet it complicates the assessment of true operational efficiency. Analysts should adjust for these non-cash expenses to better understand the actual cash runway, as the reported net income figures are heavily influenced by these accounting-driven compensation charges.
While the market currently assigns a premium to the AOC platform's potential, the risk of anti-drug antibody formation remains a critical, non-consensus factor that could fundamentally undermine the long-term growth durability of the company's pipeline, as suggested by the inherent volatility in clinical-stage biotech valuations.
Short-sellers may focus on the potential for immunogenicity to limit the chronic use of these therapies, which would significantly impair the total addressable market. Investors should monitor future clinical readouts for any signs of systemic toxicity or reduced efficacy over time, as these would challenge the current platform-based valuation thesis.
Quick answers to the most common questions about buying RNA stock.
For fiscal year 2025, Atrium Therapeutics, Inc. (RNA) reported total revenue of $18.6M. This represents a 4812.4% increase compared to $0.4M in 2018.
Atrium Therapeutics, Inc. (RNA) reported a net loss of $76.7M for the fiscal year ending 2025.
Atrium Therapeutics, Inc. (RNA) reported an operating income of $-76.8M, resulting in an operating profit margin of -412.6%. This margin reflects the operational efficiency of the business before interest and taxes.
Atrium Therapeutics, Inc. (RNA) generated $18.6M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.